Improving
Health Through
Genomics

About

contributing in the fields of cancer prevention, early detection, and treatment, as well as working to advance the selection of therapeutic drugs based on individual genomic data and the latest in domestic and international research.

The importance and social significance of cancer prevention is increasing worldwide. In accordance with our company’s vision to deliver more accurate and faster technologies which can reach more people: In cooperation with domestic and international research institutes, medical institutions, and our partner companies, we aim to deliver the latest in diagnostic technologies.

Utilizing the latest
in preventive medicine
and DNA analysis technologies,
we aim to establish and popularize
new diagnostic methods.

Information

Company

Corporate Name	Crecon Genomics Inc.
Business	Genomic Medicine Information Services.
Established	April 12, 2023
Address	405, Miyamasuzaka Building 2-19-15 Shibuya, Shibuya-ku, Tokyo 150-0002, Japan.

Location

: 405, Miyamasuzaka Building 2-19-15 Shibuya,
Shibuya-ku, Tokyo 150-0002, Japan.

Board of Directors

Hitoshi Kimura	Representative Director and Chairman
Toshiaki Ito	President & Chief Executive Officer
Takashi Tsuchiya	Board Director, Executive Vice-President
Tetsuji Matsuyama	Board Director, Chief Operation Officer
Takuro Tamura	Board Director, Chief Information Officer
Teruyoshi Hishiki	Board Director, Chief Science Officer
Takaaki Sato	Independent Director
Tsuyoshi Nishitani	Auditor

Affiliates

CRECON RESEARCH & CONSULTING INC.

http://www.crecon.co.jp/english/

Pharmaceutical information services
CRECON Medical Assessment Inc.

https://www.crecon-ma.co.jp/english/

Research, analysis, and consulting services focused on pharmacoeconomics (health care economics evaluation)

Partner

Partner — iLAC is a genuinely unique entity devoted to fertile promotion of “precision medicine” (meticulously individualized medical procedures), which facilitates selection of optimum treatments, medications, and other advances tailored to the needs of specific patients. With that vision in mind, iLAC provides high-throughput genome analysis, expression analysis, and genome structure analysis applied to multiple specimens. Likewise mobilized are proteome, metabolomic, and other omics analysis networks effective in formulating pathological evaluation systems on the strength of multidimensional markers.Employing its high value-added, extensive and detailed databases, the laboratory contributes to the discovery of new therapeutic targets, fulfillment of healthy longevity against the backdrop of today’s aging society, and feasible curbs on healthcare costs.